文献速递肿瘤 PET/CT

肝细胞癌经动脉化疗栓塞联合贝伐珠单抗治疗前后[11C]-乙酸盐PET与[18F]-FDG PET的评估价值

The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-05-29

前瞻性研究纳入22例病理确诊肝细胞癌患者,随机接受经动脉化疗栓塞(TACE)联合贝伐珠单抗(n=11)或安慰剂(n=11),治疗前后行[11C]-乙酸盐PET和[18F]-FDG PET。结果显示[11C]-乙酸盐PET患者相关灵敏度68%、[18F]-FDG PET 45%、两者联合73%;TACE联合贝伐珠单抗组乙酸盐阳性病灶转阴率显著高于安慰剂组(p<0.05)。作者认为联合[18F]-FDG与[11C]-乙酸盐PET可能有助于肝细胞癌管理并提供预后和分子异质性信息。

要点

  • [11C]-乙酸盐PET、[18F]-FDG PET及两者联合的患者相关灵敏度分别为68%、45%和73%。
  • TACE联合贝伐珠单抗组乙酸盐阳性病灶转阴率显著高于TACE联合安慰剂组(p<0.05)。
  • 乙酸盐PET阴性患者中,贝伐珠单抗组平均OS 259±118天,显著短于安慰剂组668±217天(p<0.05)。

核心结论

  • 研究提示联合[18F]-FDG与[11C]-乙酸盐PET可能有助于肝细胞癌患者的管理,并可能提供相关的预后与分子异质性信息。

研究设计与样本

  • 前瞻性研究纳入22例经组织病理学证实的肝细胞癌患者(女性3例、男性19例;年龄62±8岁),接受TACE联合贝伐珠单抗(n=11)或安慰剂(n=11)治疗。
  • 治疗前后分别行[11C]-乙酸盐PET和[18F]-FDG PET检查,组间比较酌情采用t检验和卡方检验。
  • 总生存期(OS)定义为自开始贝伐珠单抗或安慰剂治疗至死亡或末次随访的时间。

主要发现

  • [11C]-乙酸盐PET、[18F]-FDG PET及两者联合的患者相关灵敏度分别为68%、45%和73%。
  • TACE联合贝伐珠单抗组中[11C]-乙酸盐阳性病灶转为阴性的比例显著高于TACE联合安慰剂组(p<0.05)。
  • 在[11C]-乙酸盐PET阴性患者中,TACE联合贝伐珠单抗组平均OS为259±118天,显著短于TACE联合安慰剂组的668±217天(p<0.05)。
  • 在TACE联合安慰剂组中,[18F]-FDG PET阳性患者与阴性患者的平均OS存在显著差异(p<0.05)。
  • 肝细胞癌病灶表现出不同的示踪剂亲和力,显示肝细胞癌的异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This prospective study was to investigate the value of [11C]-acetate PET and [18F]-FDG PET in the evaluation of hepatocellular carcinoma (HCC) before and after treatment with transarterial chemoembolization (TACE) and vascular endothelial growth factor (VEGF) antibody (bevacizumab). METHODS: Twenty-two patients (three women, 19 men; 62 ± 8 years) with HCC verified by histopathology were treated with TACE and bevacizumab (n = 11) or placebo (n = 11). [11C]-acetate PET and [18F]-FDG PET were performed before and after TACE with bevacizumab or placebo. Comparisons between groups were performed with t-tests and Chi-squared tests, where appropriate. Overall survival (OS) was defined as the time from start of bevacizumab or placebo until the date of death/last follow-up, respectively. RESULTS: The patient-related sensitivity of [11C]-acetate PET, [18F]-FDG PET, and combined [11C]-acetate and [18F]-FDG PET was 68%, 45%, and 73%, respectively. There was a significantly higher rate of conversion from [11C]-acetate positive lesions to negative lesions in patients treated with TACE and bevacizumab as compared with that in patients with TACE and placebo (p < 0.05). In patients with negative acetate PET, the mean OS in patients treated with TACE and bevacizumab was 259 ± 118 days and was markedly shorter as compared with that (668 ± 217 days) in patients treated with TACE and placebo (p < 0.05). In patients treated with TACE and placebo, there was significant difference in mean OS in patients with positive FDG PET as compared with that in patients with negative FDG PET (p < 0.05). The HCC lesions had different tracer avidities showing the heterogeneity of HCC. CONCLUSIONS: Our study suggests that combining [18F]-FDG with [11C]-acetate PET could be useful for the management of HCC patients and might also provide relevant prognostic and molecular heterogeneity information.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Li S, Peck-Radosavljevic M, Ubl P, et al. The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab. Eur J Nucl Med Mol Imaging. 2017. PMID: 28555333. doi:10.1007/s00259-017-3724-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。